Alvogen, Inc FDA Inspection Record
Alvogen, Inc is an FDA-inspected facility (FEI 3008454186) located in Morristown, NJ, US. RegDataLab tracks 5 FDA inspections at this facility.
What FDA found at this site
- Latest inspection
- Nov 21, 2024: No Action Indicated (NAI)
- Inspections on record
- 5 (2 VAI, 3 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 10, latest Dec 31, 2025
- Import refusals
- 2
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Nov 21, 2024 | No Action Indicated (NAI) | No citations listed |
| Jun 10, 2021 | Voluntary Action Indicated (VAI) | Failure to comply with REMS Implementation System (FDCA 505-1(f)(4)) |
| Sep 11, 2020 | Voluntary Action Indicated (VAI) | Failure to develop written procedures (21 CFR 314.80(b)) Late submission of 15-day report (21 CFR 314.80(c)(1)(i)) Interval (21 CFR 314.80(c)(2)) |
| Jan 18, 2017 | No Action Indicated (NAI) | No citations listed |
| May 20, 2011 | No Action Indicated (NAI) | No citations listed |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Dec 31, 2025 | Class II | D-0259-2026 | Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, Manufactured… Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets. |
| Jan 31, 2025 | Class I | D-0245-2025 | Fentanyl Transdermal System CII, 25mcg/h, packaged in a pouch, further packaged in 5-count… Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch. |
| Feb 6, 2023 | Class II | D-0353-2023 | Levothyroxine Sodium Tablets, USP 112 mcg, 90 tablets per bottle, Rx Only, Manufactured by… Sub-Potent Drug: Out of specification for assay at the 24 month interval. |
| Feb 26, 2021 | Class II | D-0649-2021 | Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1… Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low) |
| Jul 24, 2019 | Class II | D-1722-2019 | Nitrofurantoin Monohydrate/Macrycrystals Capsules, 100 mg, 100-count bottle, Rx Only… and 1 more product Failed dissolution specifications |
| Apr 19, 2019 | Class I | D-1277-2019 | FENTANYL Transdermal System, 12 mcg/h, five (12 mcg/h) systems per carton, Rx only… Product Mix-Up: Customer complaint that their carton labeled as Fentanyl Transdermal Systems, 12 mcg/h contained five patches labeled and… |
| Jun 16, 2017 | Class II | D-0939-2017 | Clindamycin Injection USP; 300 mg/2 mL (150 mg/mL). 2 mL Single-dose ADD-VANTAGE Vial, Rx… and 2 more products Lack of Assurance of Sterility |
| Mar 7, 2017 | Class III | D-0627-2017 | Nifedipine Extended-Release Tablets, 30 mg, 100-count bottles, Rx Only, Manufactured for… and 8 more products Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib |
| Apr 21, 2015 | Class II | D-1082-2015 | NITROFURANTOIN MONOHYDRATE/MACROCRYSTALS CAPSULES, 100 mg, 100 count bottle, Rx Only… Failed Dissolution Specification; 6 month time point |
| Aug 28, 2014 | Class II | D-1607-2014 | Oxycodone and Acetaminophen Tablets USP 10 mg/325 mg 100 count bottles Rx Only… Failed Content Uniformity Specifications - The lot failed to meet the acceptance criteria for Uniformity of Dosage Units at the time of… |
FDA record score
31 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
11 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class I recall D-0245-2025, this FEI as the recalling firm | Jan 31, 2025 | 15 x 1 | 15 |
| Class II recall D-0259-2026, this FEI as the recalling firm | Dec 31, 2025 | 4 x 1 | 4 |
| Class I recall D-1277-2019, this FEI as the recalling firm | Apr 19, 2019 | 15 x 0.25 | 3.8 |
| Class II recall D-0353-2023, this FEI as the recalling firm | Feb 6, 2023 | 4 x 0.6 | 2.4 |
| Inspection classified VAI | Jun 10, 2021 | 6 x 0.25 | 1.5 |
| Inspection classified VAI | Sep 11, 2020 | 6 x 0.25 | 1.5 |
| Class II recall D-0649-2021, this FEI as the recalling firm | Feb 26, 2021 | 4 x 0.25 | 1 |
| Class II recall D-1722-2019, this FEI as the recalling firm | Jul 24, 2019 | 4 x 0.25 | 1 |
| Class II recall D-0939-2017, this FEI as the recalling firm | Jun 16, 2017 | 4 x 0.25 | 1 |
| Class II recall D-1082-2015, this FEI as the recalling firm | Apr 21, 2015 | 10 years or older, so it adds no points | 0 |
| Class II recall D-1607-2014, this FEI as the recalling firm | Aug 28, 2014 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Alvogen, Inc as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Alvogen, Inc yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Alvogen, Inc
- Location
- Morristown, NJ (US)
- Source
- inspections